Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Anthera Pharmaceuticals Inc | ex99_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 9, 2017
ANTHERA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
|
001-34637
|
|
20-1852016
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
25801 Industrial Boulevard, Suite B, Hayward,
California
|
|
94545
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (510) 856-5600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 8.01.
|
Other Events.
|
On August 9, 2017, Anthera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that blisibimod has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Immunoglobulin A nephropathy. A copy of the press release is filed herewith as Exhibit 99.1.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
Press release dated August 9, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: August 9, 2017
|
|
|
Anthera Pharmaceuticals, Inc.
|
|||
|
|
|
By:
|
|
/s/ Craig Thompson
|
||
|
|
|
|
Craig Thompson
|
|||
|
|
|
|
President and Chief Executive Officer
(Principal Executive Officer)
|
|||
Exhibit Index
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
Press release dated August 9, 2017
|